中樞神經系統的藥物開發：神經變異性疾病

中樞神經系統的藥物開發：神經變異性疾病 是由出版商Espicom Business Intelligence在2006年11月所出版的。 這份英文市場調查報告書包含127 Pages 價格從美金1625起跳。

簡介

目錄

Abstract

This chapter of CNS Drug Discoveries focuses on the Alzheimer' s disease and Parkinson' s disease sectors of the market for neurodegenerative drugs.

Approximately US$6.6 billion was spent in 2005 on the symptomatic treatment of Alzheimer' s disease (AD) and Parkinson' s disease (PD). Although these neurodegenerative diseases only affect around 1% of the population their prevalence increases with age, thus these diseases are likely to become more commonplace due to patient demographics and become a greater burden on health care services.

Global Alzheimer' s and Parkinson' s market In 2005, approximately 45% of AD/PD sales were derived from the US compared to 36% in Europe and the remainder (19%) in international markets including Japan. The sale of AD and PD medication varies between each country, for example 55% of AD drug sales are derived from the US compared to 31% of PD drug sales. The treatment of AD patients is dominated by the use of acetylcholinesterase inhibitors such as Aricept (Eisai), Exelon (Novartis) and Razadyne (Johnson & Johnson) although the use of the NMDA receptor antagonist Namenda/Ebixa (Forest/Lundbeck) is gaining acceptance, particularly in the treatment of moderate to severe AD. In contrast, PD patients are treated with a cocktail of drugs but predominantly with dopaminergic drugs such as Levodopa and/or dopamine agonists either as a monotherapy or in combination with catechol O-methyltransferase (COMT) inhibitors or monoamine oxidase (MAO) inhibitors.

Over the next six years, we forecast the market will undergo a new wave of treatments as the first disease-modifying agents (those that address the underlying cause of the diseases rather than the symptoms) are launched. These include Alzhemed (Neurochem), Flurizan (Myriad Genetics) and phenserine (Axonyx) for the treatment of AD and spheramine (Schering AG) for the treatment of PD.

Table of Contents

NEURODEGENERATION

• EXECUTIVE SUMMARY
• THE FACTS
  • What is neurodegeneration and why are we interested in it?
• PATIENT STATISTICS
  • Incidence, diagnosis rates and treatment; now and in the future
• PATIENT MODEL
  • The addressable AD and PD patient population will grow by 2% per annum
    • Summary of AD patient population forecasts 2005A-2012E
    • Summary of PD patient population forecasts 2005A-2012E
• DRUG GROWTH DRIVERS
• DRUG GROWTH RISKS/DAMPENERS

GLOBAL AD/PD MARKET

• Global CNS Market (US$68.7 billion)
• GLOBAL SALES SPLIT
  • AD and PD Global sales split (2005A)
  • AD Global sales split (2005A)
  • PD Global sales split (2005A)
  • US market
    • AD US drugs sales split (2005A)
    • PD US drugs sales split (2005A)
  • European market
    • AD European drugs sales split (2005A)
    • PD European drugs sales split (2005A)
  • Japan
    • Split between AD and PD in Japan (2005A)
  • The major players
    • Market Share of AD players by sales (Dec 2005A)
    • Market Share of PD players by sales (Dec 2005A)
  • Players and Products in 2012
    • Market Share of AD players by sales (Dec 2012E)
  • Players and Products in 2012
    • Market Share of PD players by sales (Dec 2012E)
• CURRENT AD TREATMENTS
• CURRENT PD TREATMENTS
  • Leading Brands
    • Comparison of leading AD drugs
    • Comparison of leading PD drug classes
  • Patent Exposure of Current Products
    • Patent Exposure of Leading AD Brands
    • Patent Exposure of Leading PD Brands
• ANALYSIS OF LEADING BRANDS
  • AD Agents
  • PD Agents
• Acetylcholine Esterase (AChE) Inhibitors
  • Aricept (Eisai)
  • Exelon (Novartis)
  • Razadyne (Johnson & Johnson/Shire)
• NMDA Antagonist
  • Namenda/Ebixa (Forest/Lundbeck)
• Dopamine Agonists
  • Apokyn (Britannia/Vernalis)
  • Neupro (Schwarz Pharma)
  • Sifrol/Mirapex/Mirapexin (Boehringer Ingelheim)
  • Requip (GlaxoSmithKline)
• Monoaminoxidase (MAO) Inhibitors
  • Azilect (Lundbeck/Teva)
• Catechol-O-Methyltransferase (COMT) Inhibitors
  • Comtan/Comtess & Stalevo (Novartis)
• GLOBAL SALES FORECASTS OF CURRENT TREATMENTS 2005 - 2012
  • Sales Forecasts of Current Leading AD Drugs
  • Sales Forecasts of Current Leading PD Drugs 2005 - 2012
  • Model assumptions
• NEW DRUGS IN R&D
  • Drugs in Development to Treat AD and PD
• ANALYSIS OF PHASE III DRUGS
  • New Drugs in Phase III Development to Treat AD and PD
  • AD Agents
  • PD Agents
• AD Agents
  • Alzhemed (Neurochem)
  • Flurizan (Myriad Genetics)
  • Phenserine (Axonyx)
  • Xaliproden (sanofi-aventis)
• Parkinson' s Disease
  • E2007 (Eisai)
  • Istradefylline (Kyowa Hakko)
  • Safinamide (Newron)
  • SLV308 (Solvay)
  • Spheramine (Schering AG/Titan)
• GLOBAL SALES FORECASTS OF PHASE III AD and PD DRUGS 2006 - 2012
  • Sales Forecasts of Phase III Developmental AD and PD Drugs
  • Model assumptions
• ANALYSIS OF PHASE II DRUGS
  • New Drugs in Early Clinical Development to Treat AD and PD
  • AD Agents
  • PD Agents
• AD agents
  • Bapineuzumab (Wyeth/Elan)
  • Other promising Phase II drugs
  • CX717 (Cortex Pharmaceuticals)
  • EVT 101 (Evotec)
  • Ketasyn (Accera)
  • MEM 1003 (Memory Pharmaceuticals)
  • PBT2 (Prana)
  • SGS-742 (Saegis Pharmaceuticals)
• PD drugs
  • SR 57667 (sanofi-aventis)
  • Talampanel (IVAX)
  • VR040 (Vectura)
• COMPETITOR RATIO ANALYSIS PRODUCTS/DRUGS
  • CR Analysis of AD Agents Approved by 2012 - Based on Drug Class
  • CR Analysis of PD Agents Approved by 2012 - Based on Drug Class
• COMPETITOR RATIO ANALYSIS - COMPANIES
  • CR Analysis of AD and PD Agents Approved by 2012 - Based on Company
  • WINNERS & LOSERS
    • Summary of Key Companies and Drugs in the AD and PD Market by 2012
• DISCONTINUATION OF DRUGS
  • AD and PD drugs discontinued from clinical development
• NEURODEGENERATIVE APPENDIX 1
  • Phase transition probability
    • Probability of launch
• NEURODEGENERATIVE APPENDIX 2
  • AD Patient Model
    • Summary of AD Patient Population Forecasts
• NEURODEGENERATIVE APPENDIX 3
  • PD Patient Model
    • Summary of PD Patient Population Forecasts
• NEURODEGENERATIVE APPENDIX 4
  • Global AD Drugs Sales 2005-2012
    • Global AD Drug Sales 2005A-2012E
• NEURODEGENERATIVE APPENDIX 5
  • Global PD Drugs Sales 2005-2012
    • Global PD Drug Sales 2005A-2012E
• NEURODEGENERATIVE APPENDIX 6
  • Competitor Ratio Analysis Criteria
    • Key AD & PD Drugs on the Market by 2012
• NEURODEGENERATIVE GLOSSARY
• NEURODEGENERATIVE REFERENCES
• ACRONYMS

相關商品

藥物開發相關市場調查報告書

乳癌，肺癌，血管新生:藥物開發策略分析
Triple Analysis: Breast Cancer, Lung Cancer and Angiogenesis
價格 : US $ 5175
出版日期 : 2012年01月

大腸癌，肺癌，血管新生:藥物開發策略分析
Triple Analysis: Colorectal Cancer, Lung Cancer and Angiogenesis
價格 : US $ 5175
出版日期 : 2012年01月

白血病，肺癌，血管新生:藥物開發策略分析
Triple Analysis: Leukemia, Lung Cancer and Angiogenesis
價格 : US $ 5175
出版日期 : 2012年01月

Espicom Business Intelligence發行的製藥相關市場調查報告書

疼痛治療藥市場的發展：侵害受容性及神經性疼痛治療藥的開發

Evolution in the Pain Therapy Drugs Market: Nociceptive and Neuropathic Drug Development

價格 : US $ 2265

出版日期 : 2012年01月

世界非專利藥品市場

World Generic Markets

價格 : US $ 1080

出版日期 : 2012年01月

全球醫藥品市場展望

The Outlook for Pharmaceuticals Worldwide

價格 : US $ 17490

出版日期 : 2012年01月

Email Alert(Email 通知) - 最新市場調查報告書

GII 將每天定期更新最新市場調查報書資訊，選擇您有興趣的市場分類，我們將用Email的方式讓您收到最新訊息!